2026-07-22T20:10:42Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/50982024-09-27T10:07:47Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19607

00925njm 22002777a 4500 dc Rio-Machin, A. author Gomez-Lopez, G. author Munoz, J. author Garcia-Martinez, F. author Maiques-Diaz, A. author Alvarez, S author Salgado, R. N. author Shrestha, M. author Torres-Ruiz, Raul author Haferlach, C. author Larrayoz, M. J. author Calasanz, M. J. author Fitzgibbon, J. author Cigudosa, J. C. author 2017 Leukemia. 2017 10.1038/leu.2017.194 1476-5551 0887-6924 Leukemia 28630438 http://hdl.handle.net/20.500.12105/5098 CD34(+) HEMATOPOIETIC-CELLS DIFFERENTIATION LEUKEMOGENESIS THERAPY HOXA9 MODEL PBX3 The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia